Sermorelin+Ipamorelin blend

Disclaimer
This peptide blend is available strictly for research and laboratory purposes only. It has not been approved by Health Canada and has not been evaluated for safety, efficacy, or quality. Unauthorized health products may pose serious health risks if used outside controlled research environments.

Sermorelin & Ipamorelin Blend

Description

Sermorelin and Ipamorelin are synthetic peptides that, when combined, may act synergistically to stimulate growth hormone (GH) release. GH plays a central role in regulating metabolism, tissue growth, and cellular repair.

• Sermorelin: A 29–amino acid fragment of growth hormone–releasing hormone (GHRH), known as GRF (1-29). It binds to GHRH receptors in the pituitary gland, stimulating GH secretion and downstream insulin-like growth factor-1 (IGF-1) activity.
• Ipamorelin: A synthetic pentapeptide that selectively targets ghrelin (GHS-R1a) receptors in the pituitary. It functions as a growth hormone secretagogue (GHS) without significantly affecting other pituitary hormones such as ACTH or prolactin.

Because their mechanisms differ—Sermorelin via GHRH receptors and Ipamorelin via ghrelin receptors—their combined use may produce a complementary and extended GH response. Sermorelin has a short half-life (~12 minutes), while Ipamorelin exhibits a longer half-life (~2 hours), potentially prolonging GH release.

Chemical Properties

• Sermorelin: C149H246N44O42S MW: 3357.93 g/mol Synonym: GRF (1-29)
• Ipamorelin: C38H49N9O5 MW: 771.86 g/mol Synonym: N

Research Highlights (Individual Studies)

• Growth Hormone & IGF-1: Both peptides have been shown to elevate GH and IGF-1 levels in preclinical and clinical studies, though magnitude and duration vary.
• Lean Mass: Sermorelin has been associated with increases in lean body mass and skin thickness. Ipamorelin may promote weight gain through appetite stimulation and ghrelin receptor activation.
• Bone Mineralization: Ipamorelin has been linked to increased bone mineral content in animal models, potentially via weight gain and bone remodeling pathways.
• Cardiovascular & Metabolic Effects: Ipamorelin has demonstrated selective GH stimulation without significant impact on cortisol or prolactin, suggesting a favorable endocrine profile.

 Benefits (Research Context Only)

•  Supports growth hormone release – may elevate GH and IGF-1 levels.
• Improves lean mass – may increase muscle tissue and skin thickness.
• Bone support – may enhance bone mineral density in experimentalmodels.
• Appetite regulation – may stimulate hunger and weight gain via ghrelin pathways.
• Extended activity – Sermorelin provides rapid GH release, while Ipamorelin prolongs the effect.